Medication info
PMS Memantine Tablet 20 mg (Memantine Hydrochloride)

PMS Memantine Tablet 20 mg (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›20mg / 1 tablet
Manufacturer / importer
Genufarma Co., Ltd.
Appearance
Orange rectangular film-coated tablet
Packaging
100 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202500257 · Approved 2025.02.07 · Insurance code 698004740

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
This medication is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1–7): Administer 5mg once daily for 7 days. Week 2 (Days 8–14): Administer 10mg once daily for 7 days. Week 3 (Days 15–21): Administer 15mg once daily for 7 days. From Week 4 onward, administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults Based on clinical data, the recommended dose for older patients aged 65 years and over is 20mg once daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If the medication is well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose-titration schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medication.

Ingredients

Manufacturer
Genufarma Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

View approved original text

This medication is used in the treatment of moderate to severe Alzheimer's disease. Alzheimer's disease is a degenerative brain disorder characterized by gradual decline in memory and cognitive function, and this medication helps to slow the progression of symptoms and improve the daily living abilities of patients. Therefore, it can contribute to enhancing the quality of life for patients.

How to take

Adult dose

This medication is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1–7): Administer 5mg once daily for 7 days. Week 2 (Days 8–14): Administer 10mg once daily for 7 days. Week 3 (Days 15–21): Administer 15mg once daily for 7 days. From Week 4 onward, administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults Based on clinical data, the recommended dose for older patients aged 65 years and over is 20mg once daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If the medication is well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose-titration schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medication.

Precautions

This medication should not be used in patients who are allergic to any of its components or have very poor liver function, as well as in patients with severely impaired kidney function. Caution is required when using this medication in patients with epilepsy or a history of seizures, or patients with a predisposition to seizures. Particularly, co-administration with NMDA receptor antagonists such as amantadine, ketamine, and dextromethorphan may increase central nervous system side effects, and should be avoided. Patients with changes in urine acidity (pH) due to dietary habits or certain diseases should closely monitor their urine status. Patients with heart disease or uncontrolled hypertension should exercise caution when using this medication, and those with an allergy to the dye Yellow No. 5 should also be careful. During the use of this medication, symptoms such as dizziness, headache, constipation, drowsiness, and hypertension may occur, and if symptoms are severe or uncomfortable, medical consultation is recommended. There may be interactions with other medications, so it is essential to inform healthcare professionals if taking NMDA antagonists, antipsychotic drugs, muscle relaxants, certain anticoagulants, and gastrointestinal medications. Women who are pregnant or may become pregnant should use this medication with caution, and it is recommended to discontinue breastfeeding if nursing. This medication should not be used in children or adolescents under 18, as its safety and efficacy in this population have not been confirmed. In case of overdose, seek immediate medical attention for proper treatment, as there is no specific antidote and treatment should be symptomatic. This medication may affect the central nervous system, so caution is advised when driving or operating machinery. Finally, this medication should be kept out of reach of children, and care should be taken to avoid transferring it to other containers as it may alter the quality.

Side effects

Dizziness, headache, constipation, drowsiness, hypertension, fungal infection, drug hypersensitivity reaction, confusion, hallucinations, psychotic reactions, balance disorder, gait abnormalities, seizures, heart failure, venous thrombosis/thromboembolism, shortness of breath, vomiting, pancreatitis, elevated liver function test results, hepatitis, fatigue, non-specific central nervous system symptoms (confusion, drowsiness, anxiety, aggression, hallucinations, gait disturbances), diarrhea, weakness, sense of fatigue, restlessness, psychosis, visual hallucinations, delirium, loss of consciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air and moisture. It is best to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Orange rectangular film-coated tablet

Package unit

100 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.